Clarivate Plc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Clarivate Plc (NYSE: CLVT) provides trusted insights and analytics to accelerate innovation and improve health worldwide. The company offers subscription-based information services and workflow solutions; these include Web of Science for citation indexing and research discovery, Cortellis for life sciences intelligence and competitive benchmarking, Derwent for patent analytics and IP protection, ProQuest for academic and public library content, and MarkMonitor for brand protection and online trademark management. Clarivate serves academic institutions, governments, life sciences and healthcare companies, and corporations across intellectual property, life sciences, academia, and government sectors; it operates globally with a presence in over 100 countries. Founded in 2016 as a spin-off from Thomson Reuters and headquartered in London, United Kingdom, the company has no major parent but maintains key subsidiaries such as ProQuest and Clarivate Analytics entities. In late 2024, Clarivate completed the acquisition of Leerink Partners to bolster its healthcare investment banking capabilities; it also launched enhanced AI-driven features in Cortellis and Web of Science platforms amid ongoing strategic expansions into predictive analytics for drug development and IP management.
Company News
Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence
Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence
Clarivate PLC (NYSE:CLVT) Stock Has Consensus Price Target of $3.02 According to Analysts
Sterne Kessler and Clarivate Announce Partnership to Develop AI-enhanced Patent Workflow Solutions
Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation
Clarivate (NYSE:CLVT) Hits New 12-Month Low – What’s Next?
Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate to Report Third Quarter 2026 Results on November 3, 2026
Clarivate PLC (NYSE:CLVT) Receives $3.02 Consensus Price Target from Brokerages
Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
Accuserve Solutions Appoints Maroun S. Mourad as an Independent Board Member
Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
First Trust Advisors LP Has $13.97 Million Stock Holdings in Clarivate PLC $CLVT
Clarivate Q2 Earnings Call Highlights
Clarivate Plc (CLVT) Q2 2026 Earnings Call Transcript
Clarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates